

(12) UK Patent Application (19) GB (11) 2 142 332 A
 (43) Application published 16 Jan 1985

(21) Application No 8416172

(22) Date of filing 25 Jun 1984

(30) Priority data

(31) 3503/83	(32) 27 Jun 1983	(33) CH
3504/83	27 Jun 1983	
3505/83	27 Jun 1983	

(71) Applicant

Sandoz Ltd (Switzerland),
 35 Lichtstrasse, CH-4002 Basle Switzerland

(72) Inventors

Georg Bolliger
 Erhard Schenker
 Rene Spiegel
 Hans Weidmann

(74) Agent and/or Address for Service

B A Yorke & Co.
 98 The Centre, Feltham, Middlesex TW13 4EP

(51) INT CL³

C07D 471/10 A61K 31/55 31/445 C07D
 487/10 (C07D 471/10 221/00) (C07D
 487/10 209/00 223/00)

(52) Domestic classification

C2C 1173 1175 121X 1341 1530 1531 1532 1600
 1730 200 202 211 215 220 221 25Y 281 282 28X
 29X 29Y 302 305 30Y 311 313 31Y 320 225 226
 22X 22Y 246 247 248 250 251 252 258 323 326
 32Y 334 339 350 351 352 355 35Y 360 361 362
 363 364 366 368 36Y 372 373 376 378 37X 37Y
 385 386 387 388 401 40Y 43X 462 464 491 511
 51X 537 553 574 584 594 612 620 623 624 628
 62X 62Y 635 638 645 648 650 652 656 658 65X
 662 675 676 678 695 723 746 761 762 763 771
 802 80Y AA BF BG KS LA LK MC MD QU QZ SJ TA TP
 YX
 U1S 2418 C2C

(56) Documents cited


None

(58) Field of search


C2C

(54) Spirosuccinimide derivatives

(57) Novel compounds of formula I



wherein A, R₂, R₅, X₁, X₂, m and n have various significances are useful in the treatment of senile dementia, Alzheimer's disease, Huntington's chorea, tardive diskinesia, hyperkinesia or mania.
 Intermediates of the formula IV



are also claimed.


GB 2 142 332 A

SPECIFICATION


Spirosuccinimide derivatives

5 This invention relates to spirosuccinimides.

The present invention provides a compound of formula I



15



20

20


R₁ is (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogens of atomic number from 9 to 35, (C₃₋₆)alkenyl or alkinyl, wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl substituted by hydroxy, 25 (C₁₋₄)alkoxy or (C₂₋₅)alkanoyl, benzyl, tetrahydrobenzocycloheptenyl or a group of formula -(CH₂)_r-X

30 wherein r is 1, 2 or 3 or alternatively also O when A is R₁-N and

30

X is hydroxy, mercapto, amino, (C₁₋₄)alkoxy, phenoxy, benzoxy, (C₁₋₄)alkylthio, phenylthio, benzylthio, (C₁₋₄)alkylamino, phenylamino, benzylamino, cyano, formyl, carbamoyl, carbamoyl mono- 35 or independently di-substituted by phenyl or (C₁₋₄)alkyl,

35



40

sulfamoyl, sulfamoyl mono- or independently di-substituted by phenyl or (C₁₋₄)alkyl, guanyl,

40



45

(C₂₋₅)alkanoyl, (C₂₋₅)alkanoyl independently substituted by 1 to 3 halogen atoms of atomic number from 9 to 35 or 2-oxo-pyrrolidinyl, benzoyl, cinnamoyl, nicotinoyl, dihydronicotinoyl, N-(C₁₋₄)alkyl dihydronicotinoyl, alkoxycarbonyl with 2 to 5 carbon atoms, benzoxy carbonyl, 50 (C₁₋₄)alkoxyxoyxalyl, (C₁₋₄)alkanoyloxy or benzyloxy,

50

R₂ is hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogen atoms of atomic number of 9 to 35, hydroxy(C₁₋₄)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, (C₁₋₄)mercaptoalkyl, (C₁₋₄)alkylthio(C₁₋₄)alkyl, amino(C₁₋₄)alkyl, mono- or independently di(C₁₋₄)alkylamino(C₁₋₄)alkyl, (C₃₋₆)alkenyl or alkinyl wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl (C₁₋₂)alkyl, phenyl or benzyl,

55

R₃ is hydrogen, (C₁₋₄)alkyl, benzyl or benzyl substituted by halogen of atomic number from 9 to 35 or methoxy,

R₄ and R₅ independently are hydrogen or (C₁₋₄)alkyl.

X₁ and X₂ are independently oxygen or sulphur,

60 m and n independently are 1, 2, 3 or 4 with the proviso that m + n is not more than 6 with the proviso that X₁ and X₂ are not both oxygen when m and n are each 2,

60

A is H-N or R₁-N wherein R₁ is unsubstituted (C₁₋₆)alkyl,

5

chloropropyl, hydroxypropyl, allyl, benzyl, ethoxycarbonyl, bromoalkyl and R₂ is hydrogen, unsubstituted (C₁₋₆)alkyl, allyl, phenyl or benzyl, or an acid addition salt thereof.

As described hereinafter reference to a particular formula and definitions relating thereto implies reference also to any provisos in the definitions.


Any alkyl, alkoxy or alkylthio group preferably has 1 or 2 carbon atoms and especially 1 carbon atom. Halogen is preferably fluorine or chlorine. Where a group is substituted it may be poly substituted, preferably up to 3 substituents, unless stated otherwise.

R₁ is for example hydrogen, methyl, ethyl substituted by halogen, cyclopropylmethyl or cyano.

15 R₂ is preferably ethyl m and n are preferably 2 and 2 respectively or 3 and 1 respectively.

Preferred compounds are compounds of formula I wherein A is as defined above and R₁ is (C₁₋₄)alkyl, (C₁₋₄)alkyl substituted by 1 to 6 halogen atoms of atomic number from 9 to 35, cyclopropylmethyl, (C₃₋₇)cycloalkyl, cyano, cyanomethyl or formyl, R₂ is hydrogen, (C₁₋₄)alkyl, (C₁₋₄)alkyl substituted by 1 to 6 halogen atoms of atomic number from 9 to 35, or

20 (C₃₋₇)cycloalkyl, R₃, R₄ and R₅ are each hydrogen, X₁ and X₂ are independently oxygen or sulphur, m and n are each 2, with the provisos that




30 (ii) X₁ and X₂ are not both oxygen when A is H-N or R₁-N


wherein R₁ is unsubstituted alkyl or chloropropyl and R₂ is hydrogen or unsubstituted alkyl, or an acid addition salt thereof.

35 The present invention also provides a process for the production of a compound of formula I or an acid addition salt thereof, which comprises

(a) for the production of a compound of formula Ia




wherein R₁₋₅, X₁, X₂, m and n are as defined above, or an acid addition salt thereof, oxidizing an appropriate compound of formula II



wherein R₁₋₅, X₁, X₂, m and n are as defined above, or an acid addition salt thereof,

(b) for the production of a compound of formula Ib




5

- 10 wherein R' is hydrogen or R₁ as defined above, and R₂₋₅,
X₁, X₂, m and n are as defined above with the provisos thereto and the further proviso that
both X₁ and X₂ are not oxygen,
or an acid addition salt thereof,
replacing at least one oxo group by a thio group in an appropriate compound of formula III

10

15

15




20

wherein R', R₅, m and n are as defined above or an acid addition salt thereof,
(c) for the production of a compound of formula IV

25

25



30

wherein R₂₋₅, m and n are as defined above, and R₁ is hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1-6 halogens of atomic number of from 9 to 35, (C₃₋₆)alkenyl or alkinyl, wherein the

35 multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl substituted by hydroxy, (C₁₋₄)alkoxy or (C₂₋₅)alkanoyl, benzyl, tetrahydronbenzocycloheptenyl,


35

with the proviso that m and n are not both 2 when R₁ is hydrogen, unsubstituted (C₁₋₆)alkyl, hydroxypropyl, chloropropyl, allyl or benzyl and R₂ is hydrogen, (C₁₋₆)alkyl, allyl,

40 phenyl or benzyl,

40

or an acid addition salt thereof,
cyclising the product obtainable by condensing a compound of formula IV



45

50


50

wherein R₁', R₃₋₅, m and n are as defined above with respect to formula I c, and R' and R'' are independently leaving groups, with an appropriate compound of formula V

55


55

wherein R₂ is as defined above with respect to formula I c,
(d) for the production of a compound of formula Id



60


- wherein R_{2-5} , m and n are as defined above and
 R_1^b is as defined above for R_1 with the proviso that m and n are not both 2 when R_1^b is unsubstituted (C_{1-6})alkyl, hydroxypropyl, chloropropyl, allyl, benzyl ethoxycarbonyl or benzoylalkyl and R_2 is hydrogen, unsubstituted (C_{1-6})alkyl, allyl, phenyl or benzyl,
5 or an acid addition salt thereof,
introducing a group of formula R_1^b into a compound of formula VI



- 15 wherein R_{2-5} , m and n are as defined above with respect to formula Id, and recovering the compound of formula I or an acid addition salt thereof.

Process (a) may be effected in conventional manner for the production of N-oxides using e.g. oxidising agents. Examples of oxidising agents include hydrogen peroxide or organic peracids such as chloroperbenzoic acid.

- 20 Process (b) is conveniently carried out using a conventional sulphur-containing agents used for analogous reactions, e.g. P_4S_{10} or a 2,4-dithiooxocyclo di- λ^5 -phosphathiane e.g. the compound of formula



also called Lawesson Reagent.

- 30 The reaction may be effected in an inert solvent, e.g. at temperatures from about 50 and 150°C. Mixtures of compounds of formula Ib may be obtained e.g. compounds of formula Ib wherein

(i) X_1 and X_2 are both sulphur

(ii) X_1 is sulphur and X_2 is oxygen

- 35 (iii) X_1 is oxygen and X_1 is sulphur.

The compounds may be separated in conventional manner, e.g. by chromatography.


Process (c) may be effected in conventional manner for analogous cyclisations. The reaction is conveniently effected by warming to a high temperature, e.g. from about 150 to about 250°C, if desired in an inert solvent.

- 40 The reaction may be effected if desired in a closed vessel e.g. an autoclave. R' and R'' may be for example hydroxy, (C_{1-4})alkoxy or amino.

Process (d) may be effected in conventional manner for the preparation of tertiary amines, e.g. by reaction with a compound of formula R_1^b-Y wherein Y is a leaving group, e.g. halogen or an organic sulphonic acid radical.

- 45 The compounds of formula I and their acid addition salts may be isolated and purified in conventional manner. The compounds of formula I may be converted into their acid addition salts in conventional manner and vice versa. Suitable acids for salt formation include hydrochloric acid, maleic acid and methane-sulphonic acid.

Starting materials of formula IV may for example be produced by reacting a compound of formula VII



- 60 wherein R_1^a , R_3 , R_4 , R_5 , m and n are as defined above with respect to formula IV, and R_x and R_y are independently cyano or lower alkoxy carbonyl, hydrolysed in acid conditions, decarboxylated and if desired treated with an alkanol, or amine or otherwise converted into another compound of formula IV.

Compounds of formula VII wherein R_3 is other than hydrogen may be obtained by
65 appropriately alkylating a compound of formula VIII

5

10

15

20

25

30

35

40


45

50

55

60


65



5

10 wherein R_1^a , R_4 , R_5 , R_x , R_y , m and n are as defined above, e.g. with an alkyl halide.


A compound of formula VIII may for example be produced by treating a compound of formula IX



15


20 with for example HCN in conventional manner.

A compound of formula IX may for example be produced by reacting a compound of formula X



25

30 and an appropriate compound of formula XI



30

35

in conventional manner.

40 The invention also provides groups of compounds comprising:


- (a) compounds of formula III as defined above or an acid addition salt thereof
- (b) compounds of formula Ib as defined above or an acid addition salt thereof

45 (c) compounds of formula Ia wherein R_1 is as defined above and when it contains the group X_1 , this is hydroxy, alkoxy, phenoxy, formyl, optionally substituted alkanoyl, benzoyl, cinnamoyl,

alkoxycarbonyl, benzoxy carbonyl, alkanoyloxy or benzyloxy as defined above, and R_2 is hydrogen, alkyl, optionally substituted by halogen, alkoxyalkyl, hydroxyalkyl, alkenyl or alkinyl, cycloalkyl, cycloalkylalkyl, phenyl or benzyl as defined above, or an acid addition salt thereof.

Insofar as the preparation of the starting materials is not particularly described these are known or may be prepared in conventional manner.

50 Furthermore we have found that the compounds of formula A



40

45

50

wherein X_1 and X_2 are each hydrogen, m and n are each 2,

60 A is HN or $\text{R}_1\text{-N}$ wherein R_1 is unsubstituted (C_{1-6})alkyl,

60

65 hydroxymethyl, chloromethyl, allyl, benzyl, ethoxycarbonyl or benzoylmethyl, R_2 is hydrogen,

65

unsubstituted (C_{1-6}), alkyl, allyl, phenyl or benzyl and acid addition salt thereof are particularly indicated for use as pharmaceuticals. These compounds are in general known. Any compound which is not specifically known may be made in analogous manner to that described above.

Compounds of formula A wherein R_1 is hydroxypropyl, chloropropyl or ethoxycarbonyl have not been previously disclosed as having pharmacological activity. The compound of formula

A wherein A is CH_3N , R_2 is ethyl, R_3 and R_4 are each hydrogen,

X₁ and X₂ are each oxygen and m and n each 2 has been shown to be clinically useful as described in earlier filed copending patent applications. The remaining compounds have been in general disclosed as having pharmacological activity, e.g. cholinergic or analgesic activity, e.g. in German Patent 1,211,646 and E. Jucker et al., Arch. Pharm. (1961), 294, 210-220, and 15 Helv.Chem.Acta (1966), 49, 1135-45.

We have now found that these compounds are useful for the treatment of senile dementia, Alzheimer's disease, Huntington's chorea, tardive diskinesia, hyperkinesia and mania as indicated in activity in tests mentioned below.

The compounds of formula I and A and their acid addition salts, hereinafter referred to as 20 compounds of the invention, exhibit pharmacologically activity and are therefore indicated for use as pharmaceuticals, e.g. for therapy.

In particular the compounds show activity in the following tests:-

(i) in the observation test in the mouse the compounds at doses from 1 to 300 mg/kg p.o. provoke a prolongation of the wake phase and an increased reactivity to external stimuli,

25 (ii) in the sleep/wake cycle test in chronically implanted rats the compounds at doses from about 1 to about 100 mg/kg p.o. increase the REM sleep phase, and

(iii) in the carbon-14 deoxyglucose rat test [according to the principles of L.Sokoloff, Journal of Cerebral Blood Flow and Metabolism 1981, 1, 7-36, H.E. Savaki et al., Brain Research 1982, 233, 347 and J.McCulloch et al., Journal of Cerebral Blood Flow and Metabolism 1981,

30 1, 133-136], the compounds at doses from about 1 to 300 mg/kg increase the carbon-14 deoxyglucose uptake in particular areas of the brain, particularly the limbic system.

The compounds of the invention are therefore indicated for use for the treatment of senile dementia, Alzheimer's disease, Huntington's chorea, tardive diskinesia, hyperkinesia, and mania.

An indicated total daily dosage is in the range from about 1 to about 100 mg of the 35 compound, conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing for example from about 0.2 to about 50 mg of the compound or in sustained release form.

The example 2 title compound is the preferred compound. The senile dementia and Alzheimer's disease indications are the preferred indications.

40 Appropriate unit doses for oral administration contain for example about 0.5 to about 15 mg of the compounds, e.g. from 1 to 10 mg. Appropriate doses for parenteral administration contain for example about 0.2 to about 30 mg of the compounds, e.g. from 0.3 to 10 mg.

The compounds of the invention may be administered in free base form or as a pharmaceutically acceptable acid addition salt. Such salts may be prepared in conventional manner and 45 exhibit the same order of activity as the free forms.

The present invention also provides a pharmaceutical composition comprising a composition of the invention in free base form or in pharmaceutically acceptable acid addition salt form in association with a pharmaceutical carrier or diluent.

The pharmaceutical compositions may be formulated in conventional manner and contain a 50 compound of the invention alone or in admixture with a pharmaceutical carrier or diluent. Oral pharmaceutical compositions may be in the form of, for example, tablets, dispersible powders, granulates, capsules, sirups, suspensions, solutions or elixiers. Liquid forms may contain for example from about 0.1 to about 5 mg/ml, e.g. 0.5 to 2 mg/ml of a compound. Parenteral pharmaceutical forms may be for example solutions or suspensions, e.g. sterile injectable 55 aqueous solutions. Rectal pharmaceutical compositions may be in the form of, for example, suppositories.

Oral pharmaceutical compositions may contain excipients such as sweetening agents, aromas, dyes, and conserving agents to provide an elegant and palatable preparation. Tablets may contain conventional pharmaceutical excipients e.g. inert diluents, e.g. calcium carbonate and

60 lactose, dispersing agents like starch or alginic acid, binding agents such as starch, polyvinylpyrrolidone, gelatin, lubricating agents such as magnesium stearate, stearic acid and talc.

The tablets may be coated in conventional manner to delay disintegration and resorption in the gastrointestinal tract and thereby to prolong activity.

Suspensions, sirups and elixirs may contain the conventional excipients, e.g. suspending agents like methyl cellulose, tragacanth and sodium alginate, wetting agents such as lecithin,

polyoxyethylene stearate, and polyoxyethylene sorbitan monooleate and conserving agents such as ethyl parahydroxy benzoate. Capsules may contain the compound mixed for example with an solid diluent such as lactose, starch and a lubricating agent such as magnesium stearate.

The pharmaceutical compositions may contain up to 90% by weight of the compound as active agent.

Preferred compositions are solid dosage forms, e.g. tablets or capsules.
Representative formulations are as follows:-

Capsules

10 Constituent

10 Weight

15	Compound of the invention, e.g. 2-ethyl-8-cyclopropylmethyl-2,8-diazaspiro(4,5)decan-1,3-dione	15
20	Lactose	133.5 mg
	Corn starch	92 mg
	Silica (e.g. Aerosil 200	
25	- Registered Trademark)	1.2 mg
	Magnesium stearate	2.3 mg
		230 mg

30 The constituents are mixed and filled into capsules.

30

Ampoules

35 Constituent

35 Weight


Compound of the invention, e.g. 2,8-dimethyl-2,8-		35
40 diazaspiro(4,5)decan-1,3-dione	10 mg	40
Sodium chloride	8 mg	

Water for injectable solutions qu.s.bis

1 ml

45 The ampoules were filled with 1 ml solution, closed and sterilized at 121 °C for 15 minutes. Thus in a further aspect the present invention provides a pharmaceutical composition comprising a compound of formula B

45




B

50

55

55



60

R₁ is (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogens of atomic number from 9 to 35, (C₃₋₆)alkenyl/r-alkinyl, wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl substituted by hydroxy,

65

(C₁₋₄)alkoxy or (C₂₋₅)alkanoyl, benzyl, tetrahydrobenzocycloheptenyl or a group of formula
-(CH₂)_r-X

5

wherein r is 1, 2 or 3 or alternatively also O when A is R₁-N_—, and

5

X is hydroxy, mercapto, amino, (C₁₋₄)alkoxy, phenoxy, benzoxy, (C₁₋₄)alkylthio, phenylthio,
10 benzylthio, (C₁₋₄)alkylamino, phenylamino, benzylamino, cyano, formyl, carbamoyl, carbamoyl
mono- or independently di-substituted by phenyl or (C₁₋₄)alkyl,

10

15 -CO-N_——, sulfamoyl, sulfamoyl mono- or independently di-substituted by phenyl or (C₁₋₄)alkyl, guanyl,

20 

20

(C₂₋₅)alkanoyl, (C₂₋₅)alkanoyl independently substituted by 1 to 3 halogen atoms of atomic
25 number from 9 to 35 or 2-oxo-pyrrolidinyl, benzoyl, cinnamoyl, nicotinoyl, dihydronicotinoyl, N-
(C₁₋₄)alkyl dihydronicotinoyl, alkoxy carbonyl with 2 to 5 carbon atoms, benzoxy carbonyl,

25

(C₁₋₄)alkoxy oxalyl, (C₁₋₄)alkanoyloxy or benzoyloxy,
R₂ is hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogen atoms of atomic number
of 9 to 35, hydroxy(C₁₋₄)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, (C₁₋₄)mercaptoalkyl, (C₁₋₄)alkylthio(C₁₋₄)al-
kyl, amino(C₁₋₄)alkyl, mono- or independently di-(C₁₋₄)alkylamino(C₁₋₄)alkyl, (C₃₋₆)alkenyl or
30 alkinyl wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, phenyl or benzyl,

30

R₃ is hydrogen, (C₁₋₄)alkyl, benzyl or benzyl substituted by halogen of atomic number of from
9 to 35 or methoxy,

35

R₄ and R₅ independently are hydrogen or (C₁₋₄)alkyl,
35 X₁ and X₂ are independently oxygen or sulphur,

m and n independently are 1, 2, 3 or 4 with the proviso that m + n is not more than 6
wherein A is other than

35

40 CH₃-N_— when R₂ is ethyl, R₃, R₄ and R₅ are each hydrogen, X₁ and X₂

40

are each hydrogen, and m and n each 2 or a pharmaceutically acceptable acid addition salt
thereof in admixture with a pharmaceutical carrier or diluent, preferably a pharmaceutical

45 composition comprising a compound of formula B as defined with the proviso that X₁ and X₂ are not each oxygen, when m and n are each 2,

45

50 A is HN_— or R₁-N_—, wherein R₁ is unsubstituted alkyl, allyl,

50

benzyl or benzoylalkyl, R₁ is hydrogen, unsubstituted alkyl, allyl, phenyl or benzyl or a
pharmaceutically acceptable acid addition salt thereof.

In the following Examples all temperatures are uncorrected and are in degrees Centigrade.

55

55

EXAMPLE 1:

2-ethyl-8-cyclopropylmethyl-2,8-diazaspiro-(4,5)decan-1,3-dione-8-oxide (process a)

A solution of 15.6 g 2-ethyl-8-cyclopropylmethyl-2,8-diazaspiro-(4,5)decan-1,3-dione (produced e.g. according to Example 27) in 100 ml chloroform at 0 to 5° is treated over 30 minutes with 37.8 g m-chloroperbenzoic acid in 300 ml chloroform. The yellow solution is stirred for 20 hours at room temperature, treated with 600 ml chloroform and shaken with 200 ml 5N potassium carbonate solution. The aqueous phase is separated and extracted twice with chloroform. The combined aqueous phases are washed with aqueous saturated sodium chloride solution, dried over sodium sulphate and concentrated to a brown oil. Chromatography on a tenfold amount of silicagel using m thylene chloride/10% methanol/1% ammonia yields a

60

65

yellow oil, which is converted into the crystalline hydrochloride of the title compound. Mpt. (C_2H_5OH /ether) 179–180°.

In analogous manner to example 1 the following compounds are made.

5 **EXAMPLE 2:**

2-ethyl-8-methyl-2,8-diazaspiro(4,5)decan-1,3-dione-8-oxide

Mpt. of hydrochloride: 238–239°.

5

EXAMPLE 3:

10 *2-(2-methoxyethyl)-8-methyl-2,8-diazaspiro(4,5)decan-1,3-dione-8-oxide*

Mpt. of hydrochloride: 204–206°.

10

EXAMPLE 4:

15 *2-ethyl-8-methyl-2,8-diazaspiro(4,5)decan-1,3-dithione, 2-ethyl-8-methyl-2,8-diazaspiro-(4,5)de-*

can-1-thion-3-one and 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decan-1-on-3-thione (process b)
 8.7 g 2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1,3-dione and 12.1 g Lawesson Reagent
 (see above) in 100 ml toluene are boiled in 100 ml toluene for 20 hours. The solvent is then
 evaporated off and the residue taken up in methylene chloride. The organic phase is washed
 with 2N sodium carbonate solution and ice water, dried over sodium sulphate, filtered and

15

20 concentrated. The yellow residue is chromatographed on a 100 fold amount of silicagel using as eluant methylene chloride containing 2% methanol and 0.2% ammonia. The title compounds are eluted in the following order in a rate of 2:1:1 and characterised as the hydrochloride salt:

2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1,3-dithione hydrochloride: Mpt. 257–260°.

2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1-thion-3-one hydrochloride: Mpt. 307–310°.

25 2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1-on-3-thione hydrochloride: Mpt. 214–215°.

25

EXAMPLE 5:

2-ethyl-2,7-diazaspiro(4,5)decan-1,3-dione (process c)

30 10 g [3-ethoxycarbonyl-3-piperidyl]-acetic acid ethyl ester and 200 ml anhydrous ethylamine, are treated at 180° for 12 hours in a steel autoclave. The excess amine is removed by a water pump vacuum at 40°C. The residue is chromatographed in a 25 fold amount of silicagel using as eluant methylene chloride containing 5% methanol/1% ammonia. The title compound is crystallised as the hydrogen maleate. Mpt. 177–180°.

30

The starting material is produced as follows:-

35 (a) *1-ethoxycarbonyl-3-piperidylidene-malonic acid diethyl ester*

100 g N-ethoxycarbonyl-piperidin-3-one and then 98.6 g malonic acid diethyl ester are added to a well stirred suspension of 3.5 litres tetrahydrofuran and 135 ml titanium tetrachloride at 0°. 185 ml pyridine are added over 30 minutes. The reaction mixture is stirred vigorously for 20 hours at room temperature.

35

40 The solvent is removed by a rotatory evaporator. The residue is treated with ice-water, dissolved in ether, and washed first with acid (2N HCl) and then sodium bicarbonate solution (10%). The ether solution is dried with sodium sulphate and treated with active charcoal. The ether is removed to give an orange brown syrup which is purified by quick chromatography 45 through silicagel using ether as eluant. The resultant yellow oil of the heading compound is used in the next step as such.

40

(b) *1-ethoxycarbonyl-3-cyano-3-piperidyl-malonic acid diethyl ester*

50 50 g of the product obtained from step (a) is dissolved in 350 ml ethanol and treated with 9.6 g acetic acid. A solution of 15.7 g sodium cyanide in 95 ml water is added dropwise at room temperature. The mixture is stirred for 90 minutes, treated with 2N HCl solution, and concentrated on a rotary evaporator. The residue is extracted with ether. The organic phase is washed neutral and dried. The ether is removed to give a yellow oil of the heading compound which is used in the next stage as such.

50

55 (c) *(3-ethoxycarbonyl-3-piperidyl)-acetic acid ethyl ester*

50 g of the product obtained in step (b) in 160 ml ethanol/water (1:2) at 60° are treated over 45 minutes with 230 ml concentrated hydrochloric acid. The mixture is boiled for 20 hours under reflux and then concentrated (after hydrolysis and decarboxylation) in a vacuum at 60° (bath temperature). The residue is used for the next stage as such or esterified with 65 ml ethanolic hydrochloric acid for 5 hours under reflux. After the reaction the solvent is removed at 60° (bath temperature). To work up, the residue is taken up in methylene chloride that contains 5% methanol, extracted twice with 2N sodium carbonate, washed neutral, dried over sodium sulphate, filtered and evaporated on a rotary evaporator. An orange oil of the ester heading

55

65 compound is obtained.


65

In analogous manner to Example 5 the following compounds wherein A is

5 H-N (designated H h reinafter) or R₁N and X₁ and X₂

5

are both oxygen are obtained:—

10	Ex	R ₁ or H	R ₂	R ₃	R ₄	R ₅	m	n	Salt form	mpt.	10
15	6	 -CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	hml	163-165°	15
20	7	CH ₃ -	-CH ₂ -CH ₃	H	H	H	3	1	ch	273-276°	20
25	8	CH ₃ -		H	H	H	2	2	hml	171-173°	25
30	9	CH ₃ -		H	H	H	2	2	hml	162-163°	30
35	10	CH ₃ -	 -(CH ₂) ₃ -N(CH ₃) ₂	H	H	H	2	2	dch	284°	35
40	11		-CH ₂ -CH ₃	H	H	H	2	2	hml	206-207°	40
	12	 -CH ₂ -	-CH ₃	H	H	H	2	2	hml	187-189°	
	13	CH≡C-CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	b	102-104°	

Ex.	R ₁ or H	R ₂	R ₃	R ₄	R ₅	m	n	Salt form	Mpt.	
5 14		-CH ₂ -CH ₃	H	H	H	2	2	ch	268°	5
10 15	CH ₃ -	-CH ₂ -CH ₂ -OCH ₃	H	H	H	2	2	ms	201-201°	10
16	CH ₃ -	-CH ₂ -CH ₂ -OH	H	H	H	2	2	hb	281-282°	
15 17		-CH ₂ -CH ₃	H	H	H	2	2	ch	191-193°	15
20 18	H	-CH ₂ -CF ₃	H	H	H	2	2	ch	217-220°	20
25 19	CH ₃	-CH ₂ -CF ₃	H	H	H	2	2	ch	269-272°	25
20 20	-CH ₂ -CH ₃	-CH ₂ -CF ₃	H	H	H	2	2	ch	178-181°	
30 21		-CH ₂ -CF ₃	H	H	H	2	2	ch	202-205°	30
35 22	CF ₃ -CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	ch	191-195°	35
35 23	Cl-CH ₂ -CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	ch	140-142°	
40 24	CH ₃ -	CH ₃ -	H	H	H	3	2	hb	199-202°	40
45 25	H	CH ₃ -	H	H	H	3	2	nds	293-295°	45
50 26		-CH ₂ -CF ₃	H	H	H	2	2	b	123-126°	50

* b = base

ch = hydrochloride

dch = dihydrochloride

hb = hydrobromide

ms = methanesulfonate

hml = hydrogen maleate

nds = naphthalene[bis][base]

disulfonate[1,8]

EXAMPLE 27:

2-ethyl-8-cyclopropylmethyl-2,8-diazaspiro-(4,5)decan-1,3-dione (process d)

A suspension of 23.3 g 2-ethyl-2,8-diazaspiro(4,5)decan-1,3-dione, 20.6 g cyclopropylmethylbromide, 27.6 g potassium carbonate and 18.3 g potassium iodide in 500 ml dimethylformamide are stirred for 2 hours at 80°.

The mixture is concentrated and the residue partitioned between water and methylene chloride. The aqueous phase is separated off and extracted twice with methylene chloride. The combined organic phases are washed with a little water, dried over sodium sulphate and concentrated to a yellow oil. Chromatography on a 20-fold amount of silicagel with methylene chloride containing 2% methanol as eluant gives the title compound as a yellow oil which is converted into the hydrogen maleate. Mpt. 163-5°.

In analogous manner to Example 27, the compounds of examples 6-17, 19-24 and 26 as well as the following compounds of formula I wherein A is

15 R₁-N and X₁ and X₂ are both oxygen are produced:-

Ex.	R ₁	R ₂	R ₃	R ₄	R ₅	m	n	Salt form	Mpt.
28	CH ₃ CH ₃ N-CO-CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	hm1	155-157°
29	OHC-	-CH ₂ -CH ₃	H	H	H	2	2	n	142-144°
30	NC-	-CH ₂ -CH ₃	H	H	H	2	2	n	125-126°

5



10

15

20

25

30



Ex.	R ₁	R ₂	R ₃	R ₄	R ₅	m	n	Salt form	Mpt.
5	31 NC-CH ₂ -	-CH ₃	H	H	H	2	2	ch	212-214°
10	32 C ₂ H ₅ O-CO-CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	b	79-80°
15	33  -CH ₂ -CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	194-196°
20	34 OHC-	-CH ₃	H	H	H	2	2	n	137-138°
25	35  -CH=CH-CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	88-92°
30	36 H ₂ N-CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	208-209°
35	37 C ₂ H ₅ -O-CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	84-85°
40	38  -NH-CO-	-CH ₃	H	H	H	2	2	n	210-211°
45	39 	-CH ₂ -CH ₃	H	H	H	2	2	n	156-157°
50	40  -CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	122-123°
55	41  -CO-	-CH ₂ -CH ₃	H	H	H	2	2	b	130-137°

Ex.	R ₁	R ₂	R ₃	R ₄	R ₅	m	n	Salt form	Mpt.
5									5
42	NH C= H ₂ N	-CH ₂ -CH ₃	H	H	H	2	2	ch	216-217°
10									10
43	HO-CH ₂ -CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	ch	215-218°
15									15
44	Cl-CH ₂ -CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	163-166°
20									20
45	(CH ₃) ₃ C-O-CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	101-104°
25									25
46	CH ₃ -CO	-CH ₂ -CH ₃	H	H	H	2	2	n	154-157°
30									30
47	(CH ₃) ₃ C-CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	109-112°
35									35
48	CH ₃ O-CO-	-CH ₂ -CH ₃	H	H	H	2	2	n	117-120°
49	CH ₃ -S-CH ₂ -	-CH ₂ -CH ₃	H	H	H	2	2	ch	168-171°
50		-CH ₂ -CH ₃	H	H	H	2	2	n	210-211°
40									40

45 * b = base
 n = neutral
 ch = hydrochloride
 hml = hydrogen maleate

CLAIMS


1. A process for the production of a compound of formula I



R₁ is (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted 1 to 6 halogens of atomic number from 9 to 35, (C₃₋₆)alkenyl or alkinyl, wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl substituted by hydroxy, 20 (C₁₋₄)alkoxy or (C₂₋₅)alkanoyl, benzyl, tetrahydrobenzocycloheptenyl or a group of formula -(CH₂)_r-X

25 wherein r is 1, 2 or 3 or alternatively also O when A is R₁-N, and

X is hydroxy, mercapto, amino, (C₁₋₄)alkoxy, phenoxy, benzoxy, (C₁₋₄)alkylthio, phenylthio, 30 benzylthio, (C₁₋₄)alkylamino, phenylamino, benzylamino, cyano, formyl, carbamoyl, carbamoyl mono- or independently di-substituted by phenyl or (C₁₋₄)alkyl,



sulfamoyl, sulfamoyl mono- or independently di-substituted by phenyl or (C₁₋₄)alkyl, guanyl,



(C₂₋₅)alkanoyl, (C₂₋₅)alkanoyl independently substituted by 1 to 3 halogen atoms of atomic number from 9 to 35 or 2-oxo-pyrrolidinyl, benzoyl, cinnamoyl, nicotinoyl, dihydronicotinoyl, N-(C₁₋₄)alkyl dihydronicotinoyl, alkoxycarbonyl with 2 to 5 carbon atoms, benzoxy carbonyl, 45 (C₁₋₄)alkoxyoxalyl, (C₁₋₄)alkanoyloxy or benzoyloxy,

R₂ is hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogen atoms of atomic number of 9 to 35, hydroxy(C₁₋₄)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, (C₁₋₄)mercaptoalkyl, (C₁₋₄)alkylthio(C₁₋₄)alkyl, amino(C₁₋₄)alkyl, mono- or independently di-(C₁₋₄)alkylamino(C₁₋₄)alkyl, (C₃₋₆)alkenyl or alkinyl wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl,

50 (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, phenyl or benzyl,

R₃ is hydrogen, (C₁₋₄)alkyl, benzyl or benzyl substituted by halogen of atomic number from 9 to 35 or methoxy,

R₄ and R₅ independently are hydrogen or (C₁₋₄)alkyl,

X₁ and X₂ are independently oxygen or sulphur,


55 m and n independently are 1, 2, 3 or 4 with the proviso that m + n is not more than 6 with the proviso that X₁ and X₂ are not both oxygen when m and n are each 2,

60 A is N-N or R₁-N wherein R₁ is unsubstituted (C₁₋₆)alkyl,

chloropropyl, hydroxymethyl, allyl, benzyl, ethoxycarbonyl, benzoylalkyl and R₂ is hydrogen, unsubstituted (C₁₋₆)alkyl, allyl, phenyl, or benzyl, or an acid addition salt thereof,


65 which comprises

(a) for the production of a compound of formula Ia



5


10 wherein R₁₋₅, X₁, X₂, m and n are as defined above, or an acid addition salt thereof, oxidizing an appropriate compound of formula II 10



15

20 wherein R₁₋₅, X₁, X₂, m and n are as defined above, or an acid addition salt thereof,

(b) for the production of a compound of formula Ib



25

30


30

wherein R' is hydrogen or R₁ as defined above, and R₂₋₅, X₁, X₂, m and n are as defined above with the provisos thereto and the further proviso that both X₁ and X₂ are not oxygen, or an acid addition salt thereof,

replacing at least one oxo group by a thio group in an appropriate compound of formula III

35


35



40

45

45



50

wherein R₂₋₅, m and n are as defined above, and R^a is hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogens of atomic number of from 9 to 35, (C₃₋₆)alkenyl or alkinyl, (C₁₋₂)alkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl substituted by hydroxy, (C₁₋₄)alkoxy or (C₂₋₅)alkanoyl, benzyl, or tetrahydrobenzocycloheptenyl,


with the proviso that m and n are not both 2 when R^a is hydrogen, unsubstituted (C₁₋₆)alkyl, hydroxymethyl, chloromethyl, allyl or benzyl and R₂ is hydrogen, (C₁₋₆)alkyl, allyl, phenyl or benzyl,

or an acid addition salt thereof,

cyclising the product obtainable by condensing a compound of formula IV

55


60



5


wherein R_1^i , R_{3-5} , m and n are as defined above with respect to formula Ic, and R^i and R^{ii} are independently leaving groups, with an appropriate compound of formula V

10



15 wherein R_2 is as defined above with respect to formula Ic,
(d) for the production of a compound of formula Id

15




20

25 wherein R_{2-5} , m and n are as defined above and
 R^b is as defined above for R_1 , with the proviso that m and n are not both 2 when R^b is unsubstituted (C_{1-6})alkyl, hydroxypropyl, chloropropyl, allyl, benzyl, ethoxycarbonyl or benzoylalkyl and R_2 is hydrogen, unsubstituted (C_{1-6})alkyl, allyl, phenyl or benzyl, or an acid addition salt thereof, introducing a group of formula R_1^b into a compound of formula VI

25

30

30



35

wherein R_{2-5} , m and n are as defined above with respect to formula Id, and recovering the compound of formula I or an acid addition salt thereof.

40 2. A process for the production of a compound of formula I or an acid addition salt thereof substantially as hereinbefore described.

40

3. A compound of formula I or an acid addition salt thereof whenever produced by the process of claim 1 or 2.

4. A compound of formula I or an acid addition salt thereof as defined in claim 1.

45 5. A compound of claim 4 wherein A is as defined in claim 1, R_1 is (C_{1-4})alkyl, (C_{1-4})alkyl substituted by 1 to 6 halogen atoms of atomic number from 9 to 35, cyclopropylmethyl, (C_{3-7})cycloalkyl, cyano, cyanomethyl or formyl, R_2 is hydrogen, (C_{1-4})alkyl, (C_{1-4})alkyl substituted by 1 to 6 halogen atoms of atomic number from 9 to 35, or (C_{3-7})cycloalkyl, R_3 , R_4 and R_5 are each hydrogen, X_1 and X_2 are independently oxygen or sulphur, m and n are each 2,

45

50 with the provisos that

50

O

55 (i) when A is R_1 is other than cyano or formyl, and

55



60 (ii) X_1 and X_2 are not both oxygen when A is HN or R_1N

60

wherein R_1 is unsubstituted alkyl or chloropropyl and R_2 is hydrogen or unsubstituted alkyl, or an acid addition salt thereof.

65 6. A compound of claim 4 which is 2-ethyl-8-cyclopropylmethyl-2,8-diazaspiro(4,5)-decan-1,3-dione-8-oxide or an acid addition salt thereof.

65

7. A compound of claim 4 which is 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decan-1,3-dione-8-oxide or an acid addition salt thereof.
8. A compound of claim 4 which is 2-(2-methoxyethyl)-8-methyl-2,8-diazaspiro(4,5)decan-1,3-dione-8-oxide or an acid addition salt thereof.
- 5 9. A compound of claim 4 which is 2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1,3-dithione or an acid addition salt thereof. 5
10. A compound of claim 4 which is 2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1-thion-3-one or an acid addition salt thereof.
11. A compound of claim 4 which is 2-ethyl-8-methyl-2,8-diazaspiro-(4,5)decan-1-one-3-thione or an acid addition salt thereof.
- 10 12. A compound of claim 4 which is 2-ethyl-2,7-diazaspiro-(4,5)decan-1,3-dione or an acid addition salt thereof.
13. A compound of claim 4 which is 2-ethyl-8-cyclopropylmethyl-2,8-diazaspiro-(4,5)decan-1,3-dione or an acid addition salt thereof.
- 15 14. A compound of formula I wherein A is R₁N_—, X₁ and X₂ are both oxygen, R₁ is
- 20  20
- 25 R₂ is —CH₂—CH₃, R₃, R₄ and R₅ each are hydrogen, m and n each two or an acid addition salt thereof. 25
15. A compound of formula I wherein A is R₁N_—, X₁ and X₂ are both oxygen, R₁ is
- 30 CH₃—, R₂ is —CH₂—CH₃, R₃, R₄ and R₅ are each hydrogen, m is 3, n is 1 or an acid addition salt thereof. 30
16. A compound of formula I wherein A is R₁N_—, X₁ and X₂ are both oxygen, R₁ is
- 35 CH₃, R₂ is
- 35  35
- 40 R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof. 40
17. A compound of formula I wherein A is R₁N_—, X₁ and X₂ are both oxygen, R₁ is
- 45 CH₃—, R₂ is
- 45  45
- 50 R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof. 50
18. A compound of formula I wherein A is R₁N_—, X₁ and X₂ are both oxygen, R₁ is
- 55 CH₃,
- 55  55
- 60 R₃, R₄ and R₅ are each hydrogen, m and n two or an acid addition salt thereof. 60
19. A compound of formula I wherein A is R₁N_—, X₁ and X₂ are both oxygen, R₁ is



5 R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof. 5

20. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is




10

15 R₂ is -CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof. 15

21. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is

CH≡C-CH₂-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

20 22. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is



25

R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

30 23. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is

CH₃-, R₂ is -CH₂-CH₂-OCH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

35 24. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is

CH₃-, R₂ is -CH₂-CH₂-OH, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

40 25. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is



45

R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

50 26. A compound of formula I wherein A is HN, X₁ and X₂ are both oxygen,

—R₂ is -CH₂-CF₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.


55 27. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is

CH₃, R₂ is -CH₂-CF₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

60 28. A compound of formula I wherein A is R₁N, X₁ and X₂ are both oxygen, R₁ is

-CH₂-CH₃, R₂ is -CH₂-CF₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

29. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is



5

R_2 is $-CH_2-CF_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

10

30. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is CF_3-CH_2- , R_2 is $-CH_2-CH_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

15

31. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is $Cl-CH_2-CH_2-$, R_2 is $-CH_2-CH_3$, R_3 , R_4 and R_5 are each hydrogen, n and n each two or an acid addition salt thereof.

20

32. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is CH_3- , R_2 is CH_3- , R_3 , R_4 and R_5 are each hydrogen, m is 3, n is 2 or an acid addition salt thereof.

25

33. A compound of formula I wherein A is HN . X_1 and X_2 are both oxygen, R_2 is CH_3 , R_3 , R_4 and R_5 are each hydrogen, m is 3, n is 2 or an acid addition salt thereof.

30

34. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is




35

R_2 is $-CH_2-CF_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

40

40

35. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen,



45

50 are each hydrogen, m and n each two or an acid addition salt thereof.

50

36. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is $OHC-$, R_2 is $-CH_2-CH_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

55

37. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is $NC-$, R_2 is $-CH_2-CH_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.


60

38. A compound of formula I wherein A is R_1N . X_1 and X_2 are both oxygen, R_1 is $NC-CH_2-$, R_2 is $-CH_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

65

39. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is C₂H₅O-CO-CH₂-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.


40. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is



15 R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

20 41. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is OCH-, R₂ is -CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

25 42. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is




35 R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

40 43. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is H₂N-CO-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

45 44. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is C₂H₅-O-CO-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

50 45. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is




50 R₂ is CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

55 46. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is

60

60 m and n each two or an acid addition salt thereof.

65 47. A compound of formula I wherein A is R₁N_mX₁X₂, X₁ and X₂ are both oxygen, R₁ is




5

R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

10 48. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

10



15

20 R₂ is -CH₂-CH₃, R₃, R₄, R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

20

25 49. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

25

30 NH C, -, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen,

30

m and n each two or an acid addition salt thereof.

35 50. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

35

OH-CH₂-CH₂, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are both oxygen, m and n each two or an acid addition salt thereof.

40 51. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

40

Cl-CH₂-CO-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

45 52. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

45

(CH₃)₃C-O-CO-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

50 53. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

50

CH₃-CO, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

55 54. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

55

(CH₃)₃C-CO-, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

60 55. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

60

CH₃O-CO, R₂ is -CH₂-CH₃, R₃, R₄ and R₅ are each hydrogen, m and n each two or an acid addition salt thereof.

65 56. A compound of formula I wherein A is R₁N X₁ and X₂ are both oxygen, R₁ is

65

$\text{CH}_3-\text{S}-\text{CH}_2-$, $\text{R}_2-\text{CH}_2-\text{CH}_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

5 57. A compound of formula I wherein A is R_1N , X_1 and X_2 are both oxygen, R_1 is 5



10

10


R_2 is $-\text{CH}_2-\text{CH}_3$, R_3 , R_4 and R_5 are each hydrogen, m and n each two or an acid addition salt thereof.

15 58. A compound of any one of claims 3 to 57 or a pharmaceutically acceptable acid addition salt thereof for use as a pharmaceutical. 15

59. A compound of any one of claims 3 to 57 or a pharmaceutically acceptable acid addition salt thereof for use in the treatment of senile dementia, Alzheimer's disease, Huntington's chorea, tardive dyskinesia or hyperkinesia, or mania.

20 60. A pharmaceutical composition comprising a compound of any one of claims 3 to 57 or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutical carrier or diluent. 20

61. A pharmaceutical composition comprising a compound of formula B




B

30

30

35

35



40 R_1 is (C_{1-6}) alkyl, (C_{1-6}) alkyl substituted by 1 to 6 halogens of atomic number from 9 to 35, (C_{3-6}) alkenyl or alkinyl, wherein the multiple bond is not adjacent to the nitrogen atom, (C_{3-7}) cycloalkyl, (C_{3-7}) cycloalkyl (C_{1-2}) alkyl, (C_{3-7}) cycloalkyl (C_{1-2}) alkyl substituted by hydroxy, (C_{1-4}) alkoxy or (C_{2-5}) alkanoyl, benzyl, tetrahydrobenzocloheptenyl or a group of formula $-(\text{CH}_2)_r-\text{X}$. 40

45

45

wherein r is 1, 2 or 3 or alternatively also O when A is R_1N , and

50 50 X is hydroxy, mercapto, amino, (C_{1-4}) alkoxy, phenoxy, benzoxy, (C_{1-4}) alkylthio, phenylthio, benzylthio, (C_{1-4}) alkylamino-phenylamino, benzylamino, cyano, formyl, carbamoyl, carbamoyl mono- or independently di-substituted by phenyl or (C_{1-4}) alkyl, 50



55

55

sulfamoyl, sulfamoyl mono- or independently di-substituted by phenyl or (C_{1-4}) alkyl, guanyl,



60

60

65 (C_{2-5}) alkanoyl, (C_{2-5}) alkanoyl independently substituted by 1 to 3 halogen atoms of atomic number from 9 to 35 or 2-oxo-pyrrolidinyl, benzoyl, cinnamoyl, nicotinoyl, dihydronicotinoyl, N- (C_{1-4}) alkyl dihydronicotinoyl, alkoxy carbonyl with 2 to 5 carbon atoms, benzoxy carbonyl, 65

(C₁₋₄)alkoxyxoxalyl, (C₁₋₄)alkanoyloxy or benzoxyloxy.

R₂ is hydrogen, (C₁₋₆)alkyl, (C₁₋₆)alkyl substituted by 1 to 6 halogen atoms of atomic number of 9 to 35, hydroxy(C₁₋₄)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, (C₁₋₄)mercaptoalkyl, (C₁₋₄)alkylthio(C₁₋₄)alkyl, amino(C₁₋₄)alkyl, mono- or independently di-(C₁₋₄)alkylamino(C₁₋₄)alkyl, (C₃₋₆)alkenyl or

- 5 alkinyl wherein the multiple bond is not adjacent to the nitrogen atom, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₂)alkyl, phenyl or benzyl, 5

R₃ is hydrogen, (C₁₋₄)alkyl, benzyl or benzyl substituted by halogen of atomic number from 9 to 35 or methoxy,

- 10 R₄ and R₅ independently are hydrogen or (C₁₋₄)alkyl, 10
X₁ and X₂ are independently oxygen or sulphur,
m and n independently are 1,2, 3 or 4 with the proviso that m + n is not more than 6

- 15 wherein A is other than CH₃-N when R₂ is ethyl, R₃, R₄ and R₅ are each hydrogen, 15

X₁ and X₂ are each oxygen, and m and n each 2 or a pharmaceutically acceptable acid addition salt thereof in admixture with a pharmaceutical carrier or diluent.

62. A pharmaceutical composition comprising a compound of formula B as defined in claim 20 56 with the proviso that X₁ and X₂ are not each oxygen, m and n are each 2, 20

A is HN or R₁-N, wherein R₁ is unsubstituted (C₁₋₆)alkyl,

- 25 hydroxypropyl, chloropropyl, allyl, allyl, phenyl or benzyl or a pharmaceutically acceptable acid addition salt thereof. 25

63. A pharmaceutical composition according to claim 59 wherein the compound is a compound of formula B wherein A, R₁, R₂, R₃, R₄, R₅, X₁, X₂, m and n are defined as in claim 30 61 with the proviso that X₁ and X₂ are not each oxygen, when m and n are each two, 30

A is HN or R₁-N wherein R₁ is unsubstituted alkyl, allyl, benzyl or benzoylallyl,

- 35 and R₂ is hydrogen, unsubstituted alkyl, allyl, phenyl or benzyl or a pharmaceutically acceptable acid addition salt thereof. 35

64. A pharmaceutical composition according to claim 59 wherein the compound is a compound of formula B wherein R₁ is hydroxypropyl, chloropropyl or ethoxy-carbonyl.

- 40 65. A compound of formula B as defined in claim 61, 62, 63 or 64 for use in the treatment of senile demantia, Alzheimer's disease, Huntington's chorea, tardive diskinesia or hyperkinesia, or mania. 40

66. A compound of formula IV as defined in claim 1 or a compound obtainable by reacting a compound of formula IV as defined in claim 1 and a compound of formula V as defined in 45 claim 1. 45

67. Compounds of formula III as defined in claim 1 or an acid addition salt thereof.

68. Compounds of formula Ib as defined in claim 1 or an acid addition salt thereof.

69. Compounds of formula IA wherein R₁ is as defined in claim 1 and when it contains the group X, this is hydroxy, alkoxy, phenoxy, formyl, optionally substituted alkanoyl, benzoyl, 50 cinnamoyl, alkoxy carbonyl, benzoxycarbonyl, alkanoyloxy or benzoxyloxy as defined in claim 1, and R₂ is hydrogen, alkyl optionally substituted by halogen, alkoxyalkyl, hydroxyalkyl, alkenyl or alkinyl, cycloalkyl, cycloalkylalkyl, phenyl or benzyl as defined in claim 1, or an acid addition salt thereof. 50

